Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986090 in Healthy Subjects
NCT02079480Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986090 in systemic lupus erythematosus (SLE) (9 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and Tolerability of Single Dose BMS-986090 at 85 days and Safety and Tolerability of Multiple Dose BMS-986090 at 106 days. Started May 2014; status: terminated.
02
Drugs
BMS-986090
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02079480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079480.